PDF (Daftar Pustaka) - Eprints undip

88
DAFTAR PUSTAKA
1. Azis MF. Masalah kanker serviks di Indonesia. Dalam : Pelatihan tes pap dan
IVA. Pra PIT XII POGI. Palembang 2001.
2. Sirait AM. Ketahanan hidup penderita kanker serviks di Rumah Sakit Dr. Cipto
Mangunkusumo Jakarta. MOGI 1997;13: 182-88.
3. Rock JA, Thompson JD. Invasive carcinoma of the cervix. In : Te Linde’s
Operative Gynecology 8th ed. Philadelphia: J.B. Lippincott Company; 1997.p.141399.
4. Mackey EV, Khoo SK, Daunter B. Tumor marker. In :Coppleson M. ed.
Gynecologic oncology, fundamental principles and clinical practice. London:
Churchill Livingstone; 1991.p.270-82.
5. Holschneider CH. Premalignant and malignant dissorders of the uterine cervix. In:
Current Obstetrics and Gynecologic, 9th ed. Boston 2003.p.894-908.
6. Bischer A, Giegerl E. Tumor marker in cervical carcinoma. Clinical Consultations
in Obstetric and Gynecology 1995.p. 7:94-100.
7. Magdelenat H, Fenton J, Ouhajjou A. Radioimmunoassay of SCC Antigen in
Squamous Cell Carcinoma of the Uterine Cervix. Excerpta Medica, 1997.p.71-4.
8. Ngan HY, Chan SY, Wong LC, Choy DT, Ma HK. Serum squamous cell
carcinoma antigen in the monitoring of radiotherapy treatment response in
carcinoma of the cervix. Gynecol Oncol. 1990;37(2):260-3.
9. Hong JH, Tsai CS, Chang JT, Wang CC, Lai CH, Lee SP, et al. The prognostic
significance of pre-and posttreatment SCC level in patients with squamous cell
carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys, 1998
Jul;41(4):823-30.
10. Micke O, Prott FJ, Schafer U, Tangerding S, Potter R, Willich N. The impact of
squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in
patients with cervical cancer. Anticancer Res, 2000;20(6D):5113-5. Avalaible from
URL :http://www.wccenter.com/cervix.html
11. Ohno T, Nakayama Y, Nakamoto S, Kato S, Imai R, Nonaka T, et al. Measurement
of serum squamous cell carcinoma antigen level as predictor of radiation response
in patients with carcinoma of the uterine cervix. Cancer, 2003 Jun;97(12):3114-20.
12. Iskandar TM, Suprijono. Peran squamous cell carcinoma (SCC) dalam evaluasi
keberhasilan terapi karsinoma serviks uteri. Dalam : Naskah lengkap KOGI
Palembang, 2001.
13. Sjamsuddin S. Prinsip-prinsip dasar kanker serviks. Kumpulan makalah Subbagian
Onkologi Bagian Obstetri dan Ginekologi FKUI/RSCM, 1996.
14. National Cancer Institute-PDQ Treatment health professionals. Cervical cancer.
2002.
[cited
July
16,
2003].
Available
from
:
http://www.meds.com/pdq/cervical_pro.html
89
15. Zarofin T. Ketahanan hidup kanker serviks tahun 1988 di RSCM Jakarta. Tugas
akhir pendidikan mahir onkologi ginekologi; Jakarta 1998.
16. Hidayat ST, Suyono B. Karakteristik kasus rujukan keganasan ginekologi di RS Dr.
Kariadi. Dalam : Naskah lengkap PIT X POGI Ujung Pandang, 1997.p.140-42.
17. Iwasaka T,Oh-unchida M, Marsuo N, Yokoyama M, Fufuda K, Hara K, et
al.Correlation between HPV positivity and state of the p53 gene in cervical
carcinoma of cell lines. Gynecol Oncol 1993.p.104-9.
18. Southern SA, Herrington CS. Disruption of cell cycle control by human papilloma
viruse with special reference to cervical carcinoma. Int J Gynecol Cancer 2000;
10:263-74.
19. Kitano Y, Fujisaki S, Nakamura N, Miyasaki K, Katsuki T, Okamura H.
Immunological disorder against the Epstein-Barr virus infection and prognosis in
patients with cervical carcinoma. Gynecol Oncol 1995,57 :150-7.
20. Andrijono. Kanker serviks. Dalam : Sinopsis Kanker Ginekologi. Badan Penerbit
FKUI Edisi pertama, Jakarta 2003.p.14-35.
21. Armstrong BK, Munoz N, Bosch FX. Epidemiology of cancer of the cervix. In :
Coppleson M. 2nd ed. Gynecologic Oncology. New York: Churchill Livingstone;
1992.p.11-26.
22. Albert B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Mollecular biology of
the cell. 3rd ed. Garland Publishing,Inc,New York & London ; 1994.p.950-99.
23. Abbas AK, Litchman AH, Pober JS, editors. Immunity to tumors. In : Cellular and
mollecular immunology. 3rd .ed.Philadelphia : Saunders ; 1997.p.382-405.
24. Fingert HJ, Pardee BA, Campisi J. Molecular biology and biochemistry of cancer.
In : Knapp J, Berkowitz RS, editors. Gynecologic oncology. 2nd ed. Boston :
McGraw-Hill ; 1993.p.3-35.
25. DiSaia PJ, Creasman WT, editors. Invasive cervical cancer. In : Clinical
gynecologic oncology 5th ed. St Louis: Mosby; 1997.p. 51-66.
26. Davis MA. Cervical neoplasia. [cited May 16, 2003]. Available from:
http://www.medicallibrary.org/journals/secure/obgyn_review_p/secure/cervicalNeo
plasia.htm.
27. Diagnosis and treatment of cervical carcinoma. In : ACOG Practise Bulletin;35.
Obstet Gynecol 2002;99(1): 855-67.
28. Krivak TC. Cervical and vaginal cancer. In : Novak’s Gynecology 13 th ed.
Philadelphia, USA: Lippincott William and Wilkin, 2002.p. 1199-211.
29. Malpica A. Pathology of cervical cancer. Clinical Consultation in Obstetric and
Gynecology, 1995; 7:101-10.
30. World Health Organization. International Histological Classification of tumours 2nd
ed. Histological typing of female genital tract tumours. Geneva, 1994: 41-54.
31. Benedet JL, Bender H, Jones III H, Ngan HYS, Pecorelli S. FIGO staging
classifications and clinical practice guidelines in the management of gynecologic
cancer. Int J Gynecol Obstet 2000; 70(2):209-62.
32. Eifel PJ. Radiation therapy. In: Berek JS, Hacker NF, editors. Practical gynecologic
oncology 3rd .ed. Philadephia: Lippincott Williams & Wilkins; 2000.p. 117-58.
90
33. Argadikoesoema SG. Faktor prediksi respons radiasi pada karsinoma nasofaring
[Disertasi] Program Pascasarjana Universitas Indonesia, 1998.
34. Hill RP. Cellular basis of radiotherapy. In : Tannock IF., Hill RP. Eds. The basic
science of oncology. New York. Mc. Graw-Hill. Inc.Health professions Division,
1992.p.259-75.
35. Millan TJM, Steel GG. Molecular aspects of radiation biology. In:Steel GG.,eds.
Basic clinical radiobiology. London: Edward Arnold, 1993.p.211-24.
36. Dowd Sb. Introduction of biologic efects: from cells to organs. In: Dowd SB.,eds.
Practical radiation protection and applied radiobiology. Philadelphia: W.B. Sunders
Company, 1994.p.67-85.
37. Belli JA. The radiobiologic basis for radiation therapy. In: Knapp RC, Berkowitz
RS, eds. Gynaecologic Oncology. 2nd ed. Singapore, McGraw Hill Inc; 1993.p.
109-18.
38. Iskandar TM. Efektivitas linear accelerator pada pengobatan karsinoma serviks
uteri. Semarang: Bagian Obstetri dan Ginekologi Fakultas Kedokteran Universitas
Diponegoro,1996,100 pp. Thesis.
39. Feldmier JJ. Radiation oncology. In : Weiss GR, ed. Clinical Oncology. London,
Prentice Hall International Inc; 1993.p.74-88.
40. Shingleton HM, Orr JW. Cancer of the cervix. Philadelphia : J.B. Lippincott
Company, 1995.
41. Perhimpunan Onkologi Radiasi Indonesia (PORI). Standar pelayanan profesi
radioterapi kanker leher rahim, 2000.
42. Moore M. Tumor immunology. In: Irvine WJ. editor. Medical immunology.
Edinburgh : T Viot Scientific Publications, 1998.p.425-63.
43. Hilders CG, Munoz IM, Nooyen Y, Fleuren GJ. Altered HLA expression by
metastatic cervical cacinoma cells as a factor in impaired immune surveillance.
Gynecol Oncol 1995;57:366-75.
44. Sarjadi. Neoplasma I : vulva, vagina seviks dan korpus uteri. Dalam : Patologi
ginekologi. Cetakan ke 2. Jakarta: Hipokrates; 1995.p.34-111.
45. Chan DW, Sell S. Tumor markers. In: Burtis CA, Ashwood ER, Aldrich JE. Eds.
Tietz Fundamentals of Clinical Chemistry. 4th ed. Philadelphia: WB Saunders,
1996.p.336-50.
46. Lisyani S. Pengertian umum petanda tumor. Dalam: Seminar Petanda Tumor dalam
Pengelolaan Onkologi. Badan Penerbit Universitas Diponegoro, Semarang
1997.p.9-19.
47. Kresno SB. Petanda tumor. Dalam: Imunologi : Diagnosis dan Prosedur
Laboratorium. Badan Penerbit Fakultas Kedokteran Universitas Indonesia, Jakarta
2001.p.378-404.
48. Santoso RI. Penentuan kadar petanda ganas. Dalam : Seminar sehari Manfaat
Pemeriksaan Tumor Marker. Jakarta, 1999.
49. Sutoto. Petanda tumor ginekologi. Dalam : Seminar Petanda Tumor Dalam
Pengelolaan Onkologi. Badan Penerbit Universitas Diponegoro, Semarang 1997.p.
28-9.
91
50. Silverman GA, Jockel JI, Domer PH, Mohr RM, Taillon-Miller P, Korsmeyer SJ.
Yeast artificial chromosome cloning of a two-megabase-sizecontig within
chromosomal band 18q21 establishes physical linkagebetween BCL2 and
plasminogen activator inhibitor type-2. Genomics 1991; 9:219-28.
51. Kuwano A, Kondo I, Kishi F. Assignment of the squamous cell carcinoma antigen
locus (SCC) to 18q21 by in situ hybridization. Genomics 1995; 30 (3): 626.
52. Fujimoto J, Sakaguchi H, Aoki I, Tamaya T. The value of platelet-derived
endothelial cell growth factor as a novel predictor of advancement of uterine
cervical cancers. Cancer Research 2000 Jul;60:3662-5. Avalaible from URL
:http://www.cancerres.aacrjournals.org/cgi/..&FIRSTINDEX=25%26resourcetype.
53. Cervical carcinoma : squamous cell carcinoma antigen. Avalaible from URL
:http://www. obstetrics.specialtylabs.com/books/ print_view.asp?id=545 - 10k
54. Einarsson R. Squamous cell carcinoma antigen (SCCA) isomers-markers for
squamous cell carcinoma. Adv Clin Exp Med 2005;14:643-8.
55. Suminami Y, Nagashima S, Murakami A, Nwata S, Gondo T, Hirakawa H, et al.
Supression of a squamous cell carcinoma (SCC)-related Serpin, SSC antigen,
inhibits tumor growth with increased intratumor infiltration of natural killer cells.
Cancer Res 2001; 61:1776-80.
56. Kusumaningrum R. Hubungan persistensi DNA Virus Humanpapilloma dengan
respon radiasi histopatologis pada penderita karsinoma serviks utero stadium
lanjut yang telah mendapat terapi radiasi atau kemoradiasi. Semarang: Bagian
Obstetri dan Ginekologi Fakultas Kedokteran Universitas Diponegoro, 2005, 75
pp. Thesis.
57. Taneja A, Rajaram S, Agarwal S, Singh KC, Sahni S, Goei N. “Quick Cycle”
neoadjuvant chemotherapy in squamous cell carcinoma of cervix. Indian J
Pharmacol 2005;37:320-4.
58. Ohara K, Tanaka YO, Tsunoda H, Nishida M, Sugahara S, Itai Y. Assessment of
cervical cancer radioresponse by serum squmous cell carcinoma antigen and
magnetic resonance imaging. Obstet Gynaecol 2002; 100:781-7.
59. Liu SS, Leung RC, Chan KY, Chiu P, Cheung AN, Tam K, et al. p73 Expression
Is Associated with the Cellular Radiosensitivity in Cervical Cancer after
Radiotherapy. Clin Cancer Res 2004;10: 3309-16
60. Dueñas-González A, Lizano M, Candelaria M, Cetina L, Arce C, Cervera E.
Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol
Cancer 2005;4:38.
61. Gaarenstroom KN, Bonfrer JMG. National Academy of Clinical Biochemistry
Guidelines for the Use of Tumor Markers in Cervical Cancer. NACB: Practice
Guidelines And Recommendations For Use Of Tumor Markers In The Clinic –
Cervical Cancer Manuscript (3J). Available from: http://www.nacb.org/
lmpg/tumor/chp3j_cervical.pdf. Accessed on 13 February 2006.
62. Esajas MD, Duk JM, de Bruijn HWA, Aalders JG, Willemse PHB, Sluiter W, et
al. Clinical Value of Routine Serum Squamous Cell Carcinoma Antigen in
92
Follow-Up of Patients With Early-Stage Cervical Cancer. J Clin Oncol 2001;
19:3960-6.
63. Mollna R, Filella X, Torres MD, Bailesta AM, Menguai P, Cases A, et al. SCC
Antigen Measured in Malignant and Nonmalignant Diseases. Clin Chem
1990;36:251-4
64. Morice P, Deyrolle C, Rey A, Atallah D, Pautier P, Camatte S, et al. Value of
routine follow-up procedures for patients with stage I/II cervical cancer treated
with combined surgery–radiation therapy. Annals of Oncology 2004;15: 218–23